Objectives. The main objective of this study is to explore the prevalence and distribution of entheseal US changes in a cohort of SLE patients, taking as controls a group including both PsA patients and healthy subjects. The secondary objective is to investigate the correlation between the US findings and the clinical and serological data in SLE patients.
Introduction
The musculoskeletal system is commonly involved in SLE [1] . Musculoskeletal manifestations occur in up to 95% of patients, representing the heralding symptoms in >50% of patients [24] .
Articular involvement is mainly characterized by arthralgias, which are usually transient, migratory, reversible and well responsive to treatment. In a minority of cases, joints may be more severely affected by a deforming and/or erosive arthropathy, respectively named Jaccoud's arthropathy (JA) and Rhupus syndrome [5] .
Together with the joint disorders, the spectrum of musculoskeletal conditions also includes: tenosynovitis, tendon rupture, tendonitis, osteonecrosis, myositis, FM and bone cysts [6] .
Enthesis is traditionally not considered among the targets of SLE [7] . However, our team recently found US evidence of unequivocal signs of entheseal involvement in a small group of SLE patients, raising the hypothesis that enthesis could be a missing target in the evaluation of SLE patients [8] .
The main objective of this study is to determine the prevalence and distribution of the US pathological changes in lower limb entheses in a cohort of SLE patients, taking as controls a group including both PsA patients and healthy subjects. The secondary objective is to evaluate the association between the entheseal sonographic changes and SLE disease activity.
Methods

Patients
We included 65 consecutive patients with SLE and 100 controls (50 PsA patients and 50 healthy subjects) matched for age, sex and BMI.
SLE and PsA classification criteria were used [9, 10] . SLE and PsA patients were enrolled in the following rheumatologic centres: 37 SLE patients and 43 PsA patients in the Rheumatology Unit of the Carlo Urbani Hospital, Jesi, Ancona, Italy; 18 SLE patients in the Institute of Rheumatology, Prague, Czech Republic; 10 SLE patients and 7 PsA patients in the Department of Pediatric and Adult Rheumatology, Motol University Hospital, Prague, Czech Republic. The group of healthy subjects was made up of voluntary staff members of the Carlo Urbani Hospital. There was no substantial difference in terms of BMI, age, sex and disease duration among the patients recruited in the different centres.
Inclusion criteria: age 518 years, stable therapy (if present) in the 4 weeks preceding the evaluation. Exclusion criteria: previous surgery or procedural interventions (e.g. corticosteroid injections) in the knee and/or ankle structures, intense physical activity in the 4 weeks preceding the clinical evaluation, ankle and/or knee synovitis at the time of the clinical evaluation, dyslipidaemia and/or previous diagnosis of crystal arthropathy (gout and/or calcium pyrophosphate crystal deposition disease).
We did not include patients with SLE and with family history for psoriasis and/or IBD or showing clinical signs suggestive of a concomitant spondyloarthropathy.
The study was conducted in compliance with local regulations. Ethics committee approval was not required as SLE and PsA patients underwent clinical and US assessment for diagnostic purposes according to our local protocols. As regards healthy subjects, we have a program of constant updating of our clinical and sonographic database that does not require a case-by-case approval from our Ethics Committee.
Clinical assessment
In each centre, one rheumatologist investigated the SLE and PsA patients' medical history, obtaining demographic and clinical information about each of them. In SLE patients, the SLE Disease Activity Index 2000 (SLEDAI-2k) was used to assess global disease activity [11] , whereas the musculoskeletal-BILAG 2004 DAI was used to evaluate musculoskeletal system disease activity [12] . According to the musculoskeletal-BILAG, patients were classified with score A (most active disease), score B (intermediate activity), score C (mild, stable disease), score D (previous involvement, currently inactive) and score E (no previous activity).
Three main forms of SLE-arthropathy were distinguished according to Van Vugt et al. [13] : non-deforming and non-erosive arthritis, JA and Rhupus syndrome. JA and Rhupus syndrome were diagnosed according to their respective definitions [14, 15] . SLE and PsA patients and healthy subjects underwent standard musculoskeletal physical examination, mainly aimed at the evaluation of the following entheses: the patellar insertion of the quadriceps tendon, the patellar insertion (proximal) of the patellar tendon, the tibial insertion (distal) of the patellar tendon, the calcaneal insertion of the Achilles tendon and of the plantar fascia. The choice to investigate lower limb entheses was based on their common involvement in rheumatic diseases [1622] , and their anatomic location, which permits relatively easy assessment both with US and physical examination.
The clinical diagnosis of enthesitis was made if one or more of the following findings were present at the physical examination: entheseal spontaneous pain; and entheseal pain generated by pressure and/or mobilization and/or contraction against resistance, with or without local swelling of the enthesis.
US evaluation
On the same day as the clinical examination, one of the rheumatologists taking part in this study (A.D.M., J.H., I.S.), blind to patients clinical and serological data, performed the US examination. The three sonographers shared similar background experience regarding the use of musculoskeletal US in rheumatic diseases. Before starting our study, they spent a training period at the Rheumatology Clinic of the Carlo Urbani Hospital, Jesi, Ancona, Italy, mainly focused on the application of US in the assessment of entheseal involvement in musculoskeletal disorders.
The US examination was performed with a My Lab Twice and MyLab Class C machine (Esaote S.p.A., Genoa, Italy), equipped with a high frequency linear probe (618 MHz), working at a Doppler frequency of 9.1 MHz. All the entheses were scanned bilaterally, both in longitudinal and transverse plans, in grey scale and power Doppler (PD) mode.
The evaluation of the knee entheses (patellar insertion of the quadriceps tendon, proximal and distal insertion of the patellar tendon) was carried out with the patient in neutral position, lying supine on the examination bed with extended lower limbs. The evaluation of the ankle entheses (calcaneal insertion of the Achilles tendon and of the plantar fascia) was performed with the patients lying in prone position with their feet hanging over the edge of the examination bed in neutral position.
Before starting this study, the investigators reached a consensus on the interpretation of the US findings. US entheseal pathological changes were identified according to the definitions for enthesitis in spondyloarthritis proposed by the OMERACT US Task Force [23] . According to the OMERACT definitions, the US pathological changes were divided into those indicative of active enthesitis (PD signal at the enthesis, entheseal hypoechogenicity and entheseal thickening) and those indicative of structural damage (bone erosion, enthesophyte and calcification).
In the three groups of patients, two enthesitis scores were calculated. In the first score [grey scale -power Doppler (GS-PD) enthesitis score], 1 point was attributed to the presence of entheseal thickening and/or hypoechogenicity, 1 point to the presence of calcifications and/or enthesophyte, 1 point to the presence of bone erosions and 1 point to the presence of PD signal at the enthesis, according to the scoring systems proposed by D'Agostino et al. [24] . This score ranges from 0 to 4 for each enthesis and from 0 to 40 for each patient.
In the second score (PD enthesitis score), we evaluated the sum of the PD signal, graded according to a semiquantitative scale from 0 to 3, where: grade 0: absent, grade 1: mild, grade 2: moderate and grade 3: severe [2527] . This score ranges from 0 to 3 for each enthesis and from 0 to 30 for each patient.
In SLE patients, a dichotomous score (0 = absence, 1 = presence) was provided for the following entheseal abnormalites: thickening, hypoechogenicity, enthesophyte, calcification and bone erosion. This score ranges from 0 to 1 for each enthesis and from 0 to 10 for each patient.
Laboratory parameters
In SLE patients, the following laboratory data were collected: ESR, CRP, complement proteins (C3 and C4), ANA evaluated with immunofluorescence, anti-ENA antibodies assessed with immunoassay, anti-dsDNA antibodies evaluated with immunoassay.
ESR, CRP, ANA, anti-ENA and anti-dsDNA antibodies were considered positive when their blood value was over the limit provided by each laboratory, whereas C3 and C4 were considered positive when their blood value was below the normal value limit.
Statistical analysis
Results are expressed as mean (S.D.) for quantitative variables with a normal distribution, as median and interquartile range (IQR) for quantitative variables with a nonnormal distribution and as number and/or percentage for qualitative variables. Quantitative variables were tested for normality using the ShapiroWilk normality test. The KruskalWallis multiple comparison test was used for quantitative variables and the Chi-square test for qualitative variables. Agreement between US pathological findings and clinical examination was reported as Cohen's k using Landis and Koch interpretation (<0: no agreement, 00.20: poor agreement, 0.210.40: fair agreement, 0.410.60: moderate agreement, 0.610.80: substantial agreement, 0.811.0: excellent agreement) [28] .
The correlation between the US scores of each entheseal abnormality (thickening, hypoechogenicity, enthesophyte, calcification and bone erosion) and clinical [age, sex, disease duration, BMI, steroid use (prednisone or equivalent 55 mg/day), DMARDs therapy, SLEDAI-2k and musculoskeletal-BILAG] and serological (ESR and CRP) data were calculated using Spearman's rank correlation coefficient.
Multiple linear regression analysis was performed to define predictive variables of SLE composite disease activity indices. SLEDAI-2k and musculoskeletal-BILAG were used as dependent variables. Independent variables were: age, sex, disease duration, BMI, DMARDs use, steroid use (prednisone or equivalent 55 mg/day), CRP level, GS-PD enthesitis score and PD enthesitis score. Independent variables were analysed only if their P < 0.01. Two tailed P < 0.05 were considered significant. Statistical analysis was performed using Prism software (version 7.0 for Mac, GraphPad Software, La Jolla, CA, USA) and Statistical Package for Social Science (SPSS) software (version 24.0 for Mac, Chicago, IL, USA).
Results
We evaluated 1650 entheses: 650 in SLE patients, 500 in PsA patients, 500 in healthy subjects. Of the 65 SLE patients, four were diagnosed with Rhupus syndrome and four with JA. Fifty-three out of 65 SLE patients (81.5%) referred articular manifestations in their clinical history. Table 1 shows the most representative clinical and laboratory data of the SLE patients. Regular physical activity (about twice a week) was reported by six out of SLE 65 patients (9.2%), seven out of 50 PsA patients (14.0%) and 11 out of 50 controls (22.0%).
SLE patients
US examination revealed the presence of one or more abnormalities in at least one enthesis in 44 out of 65 subjects (67.7%) and in 118 out of 650 entheses (18.2%). Of the 118 affected entheses, 51 had one pathological finding (43.2%), 38 had two pathological findings (32.2%), 19 had three pathological findings (16.1%), 9 had four pathological findings (7.6%), one had five pathological findings (0.8%) and none had six pathological findings.
Among the affected entheses, the distal insertion of the patellar tendon was the most commonly involved (36.7% of the entheses with at least one pathological US finding), followed by the calcaneal insertion of the Achilles tendon (19.6%) and the patellar insertion of the quadriceps tendon (18.8%). The proximal insertion of the patellar tendon and the calcaneal insertion of the plantar fascia were involved in 17.1 and 7.7% of the cases, respectively. Table 2 shows the prevalence and the distribution of the US abnormalities in SLE patients. The clinical examination revealed enthesitis in at least one enthesis in 22 out of 65 subjects (33.8%) and in 58 out of 650 entheses (8.9%).
PsA patients
PsA patients showed a higher prevalence of US pathological findings in comparison with SLE patients: one or more abnormalities were found in at least one enthesis in 47 out of 50 subjects (94.0%) (P < 0.001) and in 249 out of 500 entheses (49.8%) (P < 0.001).
Of the 249 affected entheses, 128 had one pathological finding (51.4%), 43 had two pathological findings (17.3%), 40 had three pathological findings (16.1%), 22 had four pathological findings (8.8%), 11 had five pathological findings (4.4%) and five had six pathological findings (2.0%).
Among the affected entheses, the distal insertion of the patellar tendon was the most commonly involved area (27.3% of entheses with at least one pathological US findings), followed by the insertion of the quadriceps tendon into the upper pole of the patella (20.1%) and the proximal insertion of the patellar tendon (18.0%). The calcaneal insertion of the Achilles tendon and of the plantar fascia were involved in 17.6 and 16.8% of the cases, respectively. Table 3 shows the prevalence and distribution of the US findings in PsA patients in comparison with SLE patients. The clinical examination revealed enthesitis in at least one enthesis in 32 out of 50 subjects (64.0%) and in 99 out of 500 entheses (19.8%).
Healthy subjects
Healthy subjects showed a lower prevalence of US pathological findings in comparison with SLE patients: one or more abnormalities were found in at least one enthesis in 22 out of 50 subjects (44.0%) (P = 0.011) and in 65 out of 500 entheses (13.0%) (P = 0.018).
Of the 65 affected entheses, 30 had one pathological finding (46.2%), 24 had two pathological findings (36.9%), 10 had three pathological findings (15.4%), one had four pathological findings (1.5%), none had five and/or six pathological findings.
The distal insertion of the patellar tendon and the calcaneal insertion of the Achilles tendon were the most commonly involved areas (24.6% of the entheses with at least one US pathological findings), followed by the patellar insertion of the quadriceps tendon (20.0%). The proximal insertion of the patellar tendon and the calcaneal insertion of the plantar fascia were involved in 15.3% of the cases. Table 4 indicates the prevalence and distribution of the US findings in healthy subjects in comparison with SLE patients.
The clinical examination revealed enthesitis in at least one enthesis in four out of 50 subjects (8.0%) and in 18 out of 500 entheses (3.6%).
Relationship between US findings and clinical enthesitis in SLE patients
In SLE patients, we evaluated the agreement between the US findings and the presence of enthesitis diagnosed by the clinical examination. The concordance was low considering any of the US pathological findings (k = 0.29, 95% CI: 0.20, 0.39; P < 0.001), very low considering at least one of the US pathological findings indicative of structural damage (k = 0.08, 95% CI: 0, 0.26; P < 0.001) and modest considering at least one of the US pathological findings indicative of active enthesitis (k = 0.35, 95% CI: 0.25, 0.46; P < 0.001).
Among the US pathological findings indicative of active enthesitis, PD signal showed the best concordance (k = 0.38, 95% CI: 0.26, 0.50; P < 0.001). Patients with clinical signs of enthesitis showed a higher prevalence of US findings indicative of active enthesitis (P < 0.001), such as PD signal (P < 0.001), entheseal thickening (P < 0.001) and entheseal hypoechogenicity (P = 0.002) compared with patients without clinical signs of enthesitis. There was no statistical difference regarding the prevalence of US findings indicative of structural damage (enthesophyte, bone erosion and calcification) between the two groups.
In patients without clinical signs of enthesitis (in each of their entheses), one or more US changes were found in at least one enthesis in 25 out of these 43 patients (58.1%). One or more US findings indicative of active enthesitis or structural damage were found in at least one enthesis in 18 (41.8%) and 16 (37.2%) out of these 43 patients, respectively. Values are n (%). Percentages refer to the total amount of the US findings in PsA patients (n = 507). Values highlighted in bold are statistically significant. PD: power Doppler. Values are n (%). Percentages refer to the total amount of the US findings in healthy subjects (n = 112). Values highlighted in bold are statistically significant. *Chi-square not measurable. PD: power Doppler. Values are n (%). Percentages refer to the total amount of the US findings in SLE patients (n = 224). PD: power Doppler.
SLE enthesitis scores and correlation with clinical and serological parameters
The median value of the GS-PD enthesitis score in the three groups was the following: 1.0 (IQR: 0.05.0) in SLE patients, 7.0 (IQR: 4.010.8) in PsA patients, 0.0 (IQR: 0.002.8) in healthy subjects. The median value of the GS-PD enthesitis score was significantly higher in the PsA group than in SLE patients (P < 0.001) and healthy subjects (P < 0.001). There was no statistical difference between SLE patients and healthy subjects.
The median value of the PD enthesitis score in the three groups was the following: 0.0 (IQR: 0.02.0) in SLE patients, 1.5 (IQR: 0.04.0) in PsA patients, 0.0 (0.00.0) in healthy subjects.
The median value of the PD enthesitis score was significantly higher in the SLE patients than in healthy subjects (P < 0.001) and in the PsA patients compared with healthy subjects (P < 0.001). There was no statistical difference between SLE and PsA patients.
The median value of the US entheseal abnormalities was: thickening 0. There was a positive correlation between the US score of entheseal thickening and SLEDAI-2k (R = 0.511, P < 0.001), musculoskeletal-BILAG (R = 0.262, P = 0.035) and age (R = 0.370, P = 0.002). A significant association between the US score of hypoechogenicity and SLEDAI2k (R = 0.548, P < 0.001) and musculoskeletal-BILAG (R = 0.435, P < 0.001) was also found. Finally, a positive correlation between the US score of bone erosion and age (R = 0.334, P = 0.006) and CRP (R = 0.358, P = 0.003) was detected. No significant association was found between the US scores of enthesophyte and calcification and the clinical and serological data that had been taken into account.
The linear regression analyses revealed the following data: PD enthesitis score was predictive of SLEDAI-2k (P < 0.001, b = 0.52, R 2 = 0.27, adjusted R 2 = 0.26) and musculoskeletal-BILAG (P < 0.001, b = 0.56, R 2 = 0.32, adjusted R 2 = 0.31). No statistically significant correlation was found between the disease activity indices and the other variables that had been considered: age, sex, disease duration, BMI, DMARDs use, steroid use, CRP level and GS-PD enthesitis score.
Discussion
This study provides new insights into musculoskeletal involvement in SLE patients, being the first aimed at determining both prevalence and topography of entheseal involvement using high-resolution US. The prevalence of US enthesitis was significantly higher in SLE patients than in healthy subjects: 44 out of 65 SLE patients (67.7%) vs 22 out of 50 healthy subjects (44.0%) (P = 0.011).
The US features detected in the SLE patients were predominantly those defined by the OMERACT US group as indicative of active enthesitis or active inflammation. The burden of the US findings indicating structural damage was consistent with that detected in healthy subjects and significantly lower than the one observed in PsA patients.
US enthesitis in SLE patients was mainly found at the distal insertion of the patellar tendon, as reported in our previous paper [8] . The highest prevalence of US entheseal changes was found in the PsA patients, as regards both structural damage and active inflammation.
As expected, US entheseal abnormalities were also found in healthy subjects. However, the prevalence of US findings indicating active enthesitis was significantly lower than in SLE patients. In particular, PD signal was found in 49 out of 650 entheses of SLE patients, but only in 2 out of 500 entheses of healthy subjects (P < 0.001). Fig. 1 shows the most representative US scenarios of the entheseal involvement in SLE and PsA patients and in healthy subjects.
In SLE patients, enthesitis was rarely associated with US findings of structural damage. It can be assumed that enthesitis, as well as synovitis, is at low risk of inducing permanent anatomical damage when compared with other conditions (PsA and RA).
The linear regression analysis showed that the presence of PD signal at the enthesis was an independent predictor of SLE disease activity. It remains an open question whether entheseal involvement should be interpreted in the context of the disease: is it an irrelevant clinical finding? Is it part of a wider inflammatory process also involving joints and tendons? Could it mark a specific subset of SLE-arthropathy? Should it be regarded as a biomarker of disease activity? The positive correlation between the US findings and musculoskeletal-BILAG suggests a possible link between the entheseal involvement and disease activity of the musculoskeletal system. Further investigation is needed to explore if enthesitis can mark a specific subset of SLE-arthropathy and if there is a relationship between the entheseal changes and other sonographic musculoskeletal abnormalities that can be detected in SLE patients, such as synovitis, tendinitis and tenosynovitis. A limit of this study is that only lower limb entheses were assessed, which might have led to underestimating the prevalence of enthesitis in SLE patients.
Another yet uncertain point is represented by the prognostic value of the US findings at entheseal level: is it a potential biomarker of increased risk of tendon damage/ rupture? Chronic subclinical inflammation could weaken the tendon mechanical resistance, thus representing a potential risk factor for a subsequent tendon rupture. A tight sonographic follow up of SLE patients with active enthesitis is required for a better understanding of its clinical relevance.
Conclusion
Our results suggest that enthesis is a target that should not be ignored in the evaluation of patients with SLE. The burden of entheseal US changes was significantly higher https://academic.oup.com/rheumatology in SLE patients than in healthy subjects, especially as regards active inflammation. The presence of PD signal at the enthesis may represent a potential biomarker of SLE disease activity.
